| Excerpt | Reference |
|---|
| "Forty-three patients with disseminated germ cell cancer were treated with a combination of vincristine, Adriamycin, cyclophosphamide, actinomycin-D, and medroxyprogesterone acetate." | ( Asbjornsen, G; Host, H; Klepp, O; Klepp, R; Stenwig, AE; Talle, K, 1977) |
| "A total of 102 men treated for germ cell tumor with chemotherapy containing cisplatin was referred for a secondary operation with signs of tumor in the retroperitoneum or chest." | ( Christiansen, S; Daugaard, G; Rasmussen, OV; Rørth, M; Sørensen, BL, 1992) |
| "Blood samples from 36 germ cell tumor patients receiving chemotherapy with either cisplatin or carboplatin in combination with other drugs [etoposide or vinblastine, cyclophosphamide, dactinomycin, and bleomycin (VAB-6)] were analyzed for the presence of 7 different biological markers." | ( Albertini, R; Bigbee, WL; Jensen, RH; Motzer, RJ; O'Neill, P; Parker, R; Perera, FP; Reed, E; Tang, D; Warburton, D, 1992) |
| "Sixty-six patients with germ cell tumors (GCTs) refractory to cisplatin plus etoposide/vinblastine-based therapy were treated with cisplatin, ifosfamide, and either etoposide (VIP) (50 patients) or vinblastine (VeIP) (16 patients)." | ( Bajorin, DF; Bosl, GJ; Motzer, RJ; Vlamis, V; Weisen, S, 1992) |
| "Forty patients with germ cell tumors were treated with carboplatin 1500-2000 mg/m2, etoposide 1200-1600 mg/m2 and ifosfamide 0-10 g/m2 plus mesna followed by autologous stem cell reinfusion." | ( Beyer, J; Grabbe, J; Huhn, D; Lenz, K; Siegert, W; Strohscheer, I; Weisbach, V, 1992) |
| "Ovarian germ cell tumors have been less well studied but are largely curable with surgery and chemotherapy." | ( Einhorn, LN; Loehrer, PJ; Nichols, CR; Williams, SD, 1992) |
| "Majority of patients even with advanced germ cell tumors of the ovary is now cured because of the development of effective platinum-based combination chemotherapy of PVB or BEP." | ( Hatae, M; Hokanishi, H; Kume, H; Maeda, Y; Nakagawa, S; Onishi, Y, 1992) |
| "The outlook for patients with germ cell tumors was poor before the advent of effective chemotherapy." | ( Etcubanas, E; Fontanesi, J; Jenkins, JJ; Kun, L; Marina, N; Rao, B; Thompson, EI, 1992) |
| "Sixty children with germ cell tumors were treated between January 1979 and June 1988." | ( Etcubanas, E; Fontanesi, J; Jenkins, JJ; Kun, L; Marina, N; Rao, B; Thompson, EI, 1992) |
| "For patients with advanced germ cell cancers, intensification of therapy or the development of new approaches is necessary." | ( Etcubanas, E; Fontanesi, J; Jenkins, JJ; Kun, L; Marina, N; Rao, B; Thompson, EI, 1992) |
| "We report seven patients with germ cell tumors which either recurred following a minimum of two regimens of platinum-based chemotherapy or were refractory to cisplatin." | ( Broun, ER; Einhorn, LH; Loehrer, PJ; Nichols, CR; Tricot, G; Williams, SD, 1991) |
| "Thirty-one patients with testicular germ cell tumors (11 with stage I, 7 with stage II, and 13 with stage III) which had been treated by PVB therapy were evaluated." | ( Imanaka, K; Kondo, N; Kuroda, A; Machida, T; Nakauchi, K; Yamazaki, H, 1990) |
| "Twenty-eight of 124 (23%) advanced germ cell tumor (GCT) patients who were treated on four successive platin-based induction regimens and who failed to achieve a durable complete response (CR) remain alive (median follow-up, 50 months)." | ( Bosl, GJ; Fair, W; Geller, NL; Herr, H; Morse, M; Motzer, RJ; Russo, P; Sheinfeld, J; Sogani, P; Tan, CC, 1991) |
| "Patients with metastatic germ cell tumors undergoing five-day chemotherapy with etoposide, vinblastin, bleomycin and cisplatinum were given recombinant GM-CSF (mammalian glycosylated, Sandoz/Schering-Plough) at increasing dose levels of 75, 150, 300 or 600 micrograms protein/day in a double blind placebo controlled study." | ( Jost, LM; Pichert, G; Stahel, RA, 1990) |
| "Sixty-three pediatric patients with germ cell tumors are presented with details of symptoms, histological findings, staging, serological markers, treatment, and response to therapy." | ( Exelby, P; Ghavimi, F; Luks, E; Wachtel, A; Wollner, N; Woodruff, J, 1991) |
| "Eighty-two patients with metastatic germ cell tumors (GCT) treated with two-drug therapy consisting of etoposide and cisplatin were evaluated for late relapse." | ( Bajorin, DF; Bosl, GJ; Geller, NL; Weisen, SF, 1991) |
| "Six patients, with advanced germ cell tumor refractory to prior chemotherapy including cis-platinum and etoposide, were treated by high dose chemotherapy and autologous bone marrow transplantation." | ( Isaka, S; Ishii, H; Okano, T; Osa, Y; Shimazaki, J; Yasuda, K, 1990) |
| "Thirty men with metastatic germ cell cancer were treated with cisplatin (20 mg/m2 administered intravenously, days 1-5), vinblastine, and bleomycin at 3- to 4-week intervals for four to six courses." | ( Kennedy, BJ; Torkelson, JL; Vogelzang, NJ, 1985) |
| "Forty patients with germ cell cancer (GCC) refractory to vinblastine, cisplatin, and bleomycin therapy were treated with etoposide (E), cisplatin +/- bleomycin +/- doxorubicin and were evaluated retrospectively to determine response to treatment." | ( Garnick, MB; Lederman, GS, 1986) |
| "Patients with germ cell tumors may be divided into "good risk" (high likelihood of complete response) and "poor risk" (low likelihood of complete response) based on pretreatment serum tumor markers, extent of disease, histology, and primary site." | ( Bosl, GJ; Motzer, RJ, 1987) |
| "The treatment of patients with germ cell neoplasms has improved dramatically during the last 10 years." | ( Einhorn, LH, 1987) |
| "A hCG- and AFP- producing germ cell tumor was suspected and radiation therapy with 60Co was performed." | ( Imura, H; Kuno, S; Nakao, K; Oki, S, 1987) |
| "Thirteen patients with a malignant germ cell tumor of the ovary have been treated with a combination of vinblastine, bleomycin, and cisplatin (VBP)." | ( Aalders, JG; Bouma, J; de Vries, EG; Mulder, NH; Sleijfer, DT; Verschueren, RC; Willemse, PH, 1987) |
| "In patients with primary germ cell tumors, treatment with combination chemotherapy followed by surgical debulking of residual tissue usually produces favorable results." | ( Dawson, NA; Knight, RD; McLeod, DG; Skoog, SJ; Taylor, HG; Waxman, JA, 1988) |
| "Fifteen patients with germ cell neoplasms (9 testicular primary, 4 extragonadal, 2 adult teratoma syndrome) with features indicative of a poor prognosis were treated with chemotherapy followed by surgery." | ( Bukowski, RM; Montie, JE; Smith, GW, 1988) |
| "A case of primary mediastinal germ cell tumor, which was radically treated with reconstruction of the superior vena cava (SVC) after neoadjuvant chemotherapy, is reported herein." | ( Baba, M; Fujisawa, T; Iwai, N; Ogawa, T; Saitoh, H; Saitoh, Y; Shiba, M; Yamaguchi, Y; Yamakawa, H, 1988) |
| "Standard chemotherapy for disseminated germ cell tumors (GCT) cures most patients but causes considerable acute toxicity, including treatment-related death due to septicemia during neutropenia and pulmonary fibrosis." | ( Auman, J; Bajorin, D; Bosl, GJ; Carey, R; Geller, NL; Golbey, RB; Leitner, SP; Scher, H; Vogelzang, NJ; Yagoda, A, 1988) |
| "Five cases of non-germinoma germ cell tumor which received combination chemotherapy with cisplatin were studied to elucidate the efficacy of chemotherapy." | ( Abe, H; Aida, T; Miyamachi, K, 1988) |
| "Of the patients with nonseminomatous germ cell tumors, 12 (40%) of the 30 are alive and free of disease with vinblastine/bleomycin +/- cisplatin (13 patients) or CISCAII (cisplatin, cyclophosphamide, and doxorubicin) (nine patients) alternating CISCAII/VBIV (eight patients) chemotherapy." | ( Dexeus, FH; Johnson, DE; Logothetis, CJ; Samuels, ML; Selig, DE; Swanson, DA; von Eschenbach, AC, 1985) |
| "Forty-nine patients with metastatic germ cell tumors were treated with etoposide 100 mg/m2 and cisplatin 20 mg/m2 intravenously each day for five days as "salvage" chemotherapy." | ( Bosl, GJ; Golbey, RB; Herr, H; MacDonald, G; Morse, M; Sogani, P; Vogelzang, N; Whitmore, W; Yagoda, A, 1985) |
| "Twelve patients with refractory germ cell tumors were treated with etoposide (VP16) (100 g/m2/day X 5) and very high dose cisplatin (VHD-CDDP) (40 mg/m2/day X 5) every 28 days." | ( Hortvet, L; Trump, DL, 1985) |
| "A total of 3 patients with germ cell cancer had pulmonary emboli while receiving cisplatin-containing chemotherapy." | ( Garnick, MB; Lederman, GS, 1987) |
| "Twenty-one patients with metastatic germ cell tumors achieved only partial clinical tumor regression following chemotherapy, and underwent surgical biopsy or resection of the residual tumor deposits." | ( Coates, AS; Coupland, GA; Fox, RM; Levi, JA; Ng, AB; Raghavan, D; Reddel, RR; Tattersall, MH; Thompson, JF; Woods, RL, 1983) |
| "More than 350 patients with testicular germ cell cancer have been treated with cisplatin combination chemotherapy." | ( Donohue, JP; Einhorn, LH; Mandelbaum, I; Rowland, RG; Williams, SD; Yaw, PB, 1983) |
| "Seven patients with germ cell tumors of the ovary were treated with four cycles of cisplatin, vinblastine, and bleomycin." | ( Aalders, JG; Bouma, J; Mulder, NH; Sleijfer, DT; Vriesendorp, R; Willemse, PH, 1984) |
| "Chemotherapy for a metastatic germ cell tumor of the testis was complicated by a life-threatening bronchial rupture secondary to lysis of an endobronchial tumor." | ( Doty, JD; Lane, M; Lynch, GR; Smith, FE, 1984) |
| "18 relapses of non seminomatous germ cell cancer of the testis are studied, among a group of 112 patients treated from 1974 to 1978, of which 90 are in complete remission." | ( Amiel, JL; Bellet, D; Brulé, G; Caillaud, JM; Droz, JP; Piot, G; Wibault, P, 1983) |
| "Patients with relapsed germ cell cancer (GCT) have a poor prognosis when treated solely with conventional chemotherapy; high dose chemotherapy with autologous bone marrow rescue (ABMR) has shown curative potential in patients with relapsed and refractory GCT." | ( Broun, ER; Einhorn, LH; Lazarus, HM; Loehrer, PJ; Nichols, CR; Roth, BJ; Turns, M; Williams, SD, 1994) |
| "Ten men with biopsy-proven germ cell tumors who had one or more poor prognostic features were treated with PVeBV." | ( Blayney, DW; Burke, JS; Doroshow, JH; Goldberg, DA; Leong, LA; Margolin, KA, 1993) |
| "Extragonadal germ cell tumors (EGGCT) are uncommon, occur primarily in the mediastinum and retroperitoneum, and have been noted to have variable response rates to cisplatin-based chemotherapy regimens." | ( Blumenstein, B; Bukowski, RM; Crawford, ED; Kulander, BG; Montie, J; Wolf, M, 1993) |
| "Clinical trials of chemotherapy in germ cell cancer have explored the full range of dose intensity." | ( Broun, ER; Einhorn, LH; Loehrer, PJ; Nichols, CR; Roth, BJ; Williams, SD, 1993) |
| "Eighteen patients with refractory germ cell tumors who failed initial cisplatin-based chemotherapy and a maximum of 2 salvage regimens were enrolled into a Phase II trial of paclitaxel at a dose of 170 mg/m2 by intravenous infusion over 24 hours every 21 days without growth factor support." | ( Cristou, A; Fox, S; Nichols, CR; Roth, BJ; Sandler, AB; Turns, M; Williams, SD, 1998) |
| "Male germ cell tumors (GCTs) are uniquely sensitive to cisplatin-based chemotherapy, with more than 90% of newly diagnosed cases cured." | ( Bosl, GJ; Chaganti, RS; Chen, W; Houldsworth, J; Murty, VV; Ray, B; Reuter, VE; Xiao, H, 1998) |
| "Relapsed extragonadal germ cell tumors patients (EGGCT) are treated with identical salvage chemotherapy regimens, as are patients with metastatic testicular cancer." | ( Beyer, J; Bokemeyer, C; Droz, JP; Einhorn, L; Fossa, SD; Gerl, A; Hartmann, JT; Horwich, A; Kanz, L; Nichols, CR; Pont, J; Schmoll, HJ, 2001) |
| "Disseminated germ cell tumors (GCT) have come to represent the model for a curable malignancy, as cure rates with cisplatin-based chemotherapy coupled with appropriate surgery are 70% to 80%." | ( Garzotto, M; Nichols, CR, 2001) |
| "Eight patients with advanced germ cell cancer were treated with TIP that was originally reported by Motzer et al (1)." | ( Akaza, H; Hattori, K; Hinotsu, S; Kawai, K; Miyazaki, J; Shimazui, T; Tsukamoto, S, 2003) |
| "A 20-year-old man with a germ cell tumor who experienced an ischemic stroke as a complication of cisplatin/etoposide/bleomycin based chemotherapy is reported." | ( Borges, LR; Dzik, C; Gabbai, AA; Malheiros, SM; Nalli, DG; Santos, AJ, 2003) |
| "In the first phase six patients with germ cell tumors treated by chemotherapy were included." | ( Drgona, L; Ebringer, L; Greksak, R; Koza, I; Mardiak, J; Mego, M; Nemova, I; Oravcova, E; Trupl, J; Zajac, V, 2005) |
| "Twenty-five patients with germ cell tumors who had marker-free residual masses after undergoing chemotherapy were followed for up to 10 years (median, 21 months)." | ( Fujinami, K; Miura, T; Osada, Y; Takizawa, A, 2005) |
| "Testicular germ cell cancers remain one of the few solid tumors routinely cured in advanced stages with conventional cisplatin-based chemotherapy." | ( DiRenzo, J; Kerley-Hamilton, JS; Li, N; Pike, AM; Spinella, MJ, 2005) |
| "Stage I and II testicular germ cell tumors (GCTs) are almost always cured with appropriate treatment and most ongoing research regarding these tumors focuses on minimizing treatment toxicity." | ( Gilligan, T, 2005) |
| "Five male patients with advanced germ cell tumor underwent 1-6 courses of high dose chemotherapy including paclitaxel (T-ICE; 175 mg/m2 of paclitaxel, 1250 mg/m2 of carboplatin, 1500 mg/m2 of etoposide and 7." | ( Fujisawa, M; Furukawa, J; Hara, I; Kumano, M; Yamada, Y; Yamanaka, K, 2005) |
| "Although the majority of testicular germ cell tumors (TGCTs) are curable by cisplatin-based chemotherapy, in a few cases, the occurrence of cisplatin resistance results in a poor outcome." | ( Luetzkendorf, J; Mueller, LP; Mueller, T; Schmoll, HJ; Simon, H; Voigt, W, 2006) |
| "Testicular germ cell tumors (GCTs) are highly sensitive to cisplatin-based chemotherapy." | ( Bokemeyer, C; Hartmann, JT; Honecker, F; Lauber, K; Malenke, E; Mayer, F; Mueller, S; Schittenhelm, M; Wesselborg, S, 2006) |
| "82 chemotherapy-naive patients with germ cell cancer scheduled to 4 cycles of multiple-day cisplatin-based chemotherapy (20 or 40 mg/m(2)/day for 5 days) given every 3 weeks were included." | ( Dombernowsky, P; Handberg, J; Herrstedt, J; Langer, SW; Nielsen, HA; Ottesen, S; Sigsgaard, TC, 2007) |
| "Fifteen patients with nonseminomatous germ cell tumors of the testis and elevated serum tumor markers as the only evidence of persistent disease following radical orchiectomy (clinical stage IS cancer), were treated at our institution from March 1995 to February 2003." | ( Managadze, L; Mezvrishvili, Z, 2006) |
| "Metastatic germ cell tumors (GCT) are curable, however GCTs refractory to cisplatin-based chemotherapy have a poor prognosis." | ( Bee, T; Black, CC; Dmitrovsky, E; Ewings, KE; Freemantle, SJ; Hattab, EM; Kelley, MR; Krizan, KA; Memoli, VA; Spinella, MJ; Vaseva, AV, 2007) |
| "Even though testicular nonseminomatous germ cell tumors (NSGCTs) usually have a good prognosis and high curability rates, unpredicted complications owing to chemotherapy regimens might complicate the course." | ( Azak, A; Deren, T; Oksüzoğlu, B; Oneç, BM; Zengin, N, 2008) |
| "Patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy but the outcome remains unsatisfactory for patients with relapsed disease." | ( Beutel, G; Fenner, MH; Grünwald, V, 2008) |
| "Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%." | ( Bogner, C; Bokemeyer, C; Fiedler, W; Frickhofen, N; Hübel, K; Isernhagen, J; Kilic, N; Kobold, S, 2011) |
| "A testicular mixed germ cell tumor was diagnosed on the basis of the histological features of the tumor removed by high orchiectomy, and systemic chemotherapy with bleomycin, etoposide, and cisplatin (BEP) was initiated." | ( Akaza, H; Bando, M; Itoh, K; Kawai, K; Kondo, Y; Nakayama, M; Saito, T; Sugiyama, Y, 2010) |
| "Although germ cell tumors (GCT) are among the most curable solid tumors, a subset of patients with GCT experience relapse or progression despite appropriate cisplatin-based therapy or first-line salvage therapy." | ( Vaughn, DJ; Veenstra, CM, 2011) |
| "Advanced germ cell tumors (GCTs) are curable with the appropriate integration of cisplatin-based chemotherapy and postchemotherapy surgical resection of residual masses." | ( Nguyen, CT; Stephenson, AJ, 2011) |
| "Refractory germ cell tumor (GCT) patients have a poor prognosis and limited treatment options." | ( Bajorin, DF; Bosl, GJ; Carousso, M; Feldman, DR; Ginsberg, MS; Motzer, RJ; Patil, S; Sheinfeld, J; Trinos, MJ, 2012) |
| "Late relapses following stage I germ cell tumors were associated with seminoma, older age, and worse outcome after induction chemotherapy." | ( Bulanov, A; Burova, A; Fainshtein, I; Fedyanin, M; Figurin, K; Garin, A; Kanagavel, D; Sergeev, U; Tjulandin, S; Tryakin, A; Zakharova, T, 2013) |
| "In relapsed germ cell tumors, salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) is a well-established regimen for patients with favorable features such as a primary testicular tumor and prior complete remission (CR) after the initial chemotherapy." | ( Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS, 2011) |
| "Patients with relapsed germ cell tumors (GCT) are potentially curable despite the failure of initial cisplatin based therapy." | ( Lim, L; Powles, T; Rashid, S, 2012) |
| "Testicular germ cell tumors (TGCT) generally respond well to chemotherapy, but tumors that express low levels of the transcription factor OCT4 are associated with chemoresistance and poor prognosis." | ( Ho, HN; Huang, YH; Kuo, HC; Ling, TY; Lu, SH; Shen, CN; Wu, YC; Yeh, SD, 2012) |
| "The treatment of primary mediastinal germ cell tumors with cisplatin-based chemotherapy followed by surgery is an established practice; however, the prognosis has remained poor." | ( Kuwano, H; Murakawa, T; Murayama, T; Nagayama, K; Nakajima, J; Sano, A; Tsuchiya, T; Yoshida, Y, 2014) |
| "Eleven patients with advanced germ cell tumor refractory or relapsed after cisplatin-based chemotherapy were treated using docetaxel, ifosfamide and nedaplatin." | ( Arai, Y; Ishidoya, S; Ito, A; Kaiho, Y; Mitsuzuka, K; Miyazato, M; Nakagawa, H; Namiki, S; Ohara, S; Saito, H; Yamada, S; Yamashita, S, 2013) |
| "Adjuvant treatments for testicular germ cell tumor have drastic effects on spermatogenesis and sperm chromatin quality." | ( Auger, J; Berthaut, I; Brugnon, F; Bujan, L; Daudin, M; Hennebicq, S; Moinard, N; Rives, N; Saias, J; Szerman, E; Walschaerts, M, 2013) |
| "Brain metastases from germ cell tumors (GCT) are rare and treatment has not yet been standardized." | ( Boyle, HJ; Droz, JP; Fléchon, A; Jouanneau, E, 2013) |
| "Some children with extracranial germ cell tumors (GCT) relapse after or do not respond to first-line treatment combining chemotherapy and surgery, of whom very few experience long-term survival despite multimodal salvage treatment." | ( Baranzelli, MC; Corradini, N; Cropet, C; Fasola, S; Faure-Conter, C; Frappaz, D; Kalfa, N; Martelli, H; Orbach, D; Patte, C; Rocourt, N; Rome, A; Thebaud, E; Vérité, C, 2014) |
| "Prolonged control of his relapsed germ cell tumor and systemic lupus erythematosus was attained with high-dose chemotherapy and hematopoietic stem cell support." | ( Athanasopoulos, A; Daladimos, T; Kosmas, C; Papachrysanthou, T; Tsavaris, N; Vlachoyiannopoulos, PG, 2013) |
| "Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy." | ( Abada, PB; Howell, SB, 2014) |
| "Patients included had disseminated germ cell cancer and received conventional chemotherapy: bleomycin, etoposide and cisplatin." | ( Daugaard, G; Feldt-Rasmussen, B; Gundgaard, MG; Lauritsen, J; Mortensen, MS; Oturai, PS, 2014) |
| "Primary central nervous system germ cell tumors (CNS-GCTs) in children and adolescents have unique clinical features and methods of treatment compared with those in adults." | ( Cai, RQ; Chen, Y; Li, PF; Lu, SY; Sun, FF; Sun, XF; Wang, J; Wu, SX; Xia, YF; Yang, QY; Zhang, F; Zhen, ZJ; Zhu, J, 2014) |
| "Testicular germ cell cancer (GCC) patients treated with cisplatin-etoposide-bleomycin chemotherapy (BEP) have excellent prognosis but have an increased risk of late-occurring morbidities, which may be associated with changes in the inflammatory profile." | ( Andersen, JL; Christensen, JF; Daugaard, G; Hojman, P; Rørth, M; Tolver, A, 2014) |
| "Patients with good risk nonseminomatous germ cell tumors received induction chemotherapy with 4 cycles of etoposide and cisplatin (EPx4) or 3 cycles of bleomycin, etoposide and cisplatin (BEPx3)." | ( Bajorin, DF; Bosl, GJ; Carver, BS; Feldman, DR; Gupta, A; Kundu, SD; Motzer, RJ; Sheinfeld, J, 2015) |
| "In adolescents aged 10-15 years germ cell tumors of the testis (TGCT) are rare and information for a risk adapted therapy limited." | ( Calaminus, G; Göbel, U; Haas, R; Harms, D; Leuschner, I; Schneider, DT; Schönberger, S; Teske, C, 2014) |
| "The survival of children with malignant germ cell tumor (GCT) increased over the past 2 decades with platinum-based chemotherapy." | ( Chang, CY; Chen, KH; Hou, JY; Liang, DC; Liu, HC; Sheu, JC; Yeh, TC, 2015) |
| "TI-TIC was active in relapsed germ cell tumors but treatment-emergent chronic renal impairment, possibly from overlapping ifosfamide and carboplatin, preclude its further use." | ( Bains, M; Bajorin, DF; Bosl, GJ; Feldman, DR; Fischer, P; Giralt, S; Glezerman, I; Hughes, A; Motzer, RJ; Patil, S; Reich, L; Sheinfeld, J; Van Alstine, L; Woo, K, 2015) |
| "Patients with germ cell tumors (GCTs) receiving cisplatin-based chemotherapy are at increased risk of thrombosis, but the underlying cellular and molecular mechanisms remain obscure." | ( Bokemeyer, C; Hauschild, J; Honecker, F; Jacobsen, C; Langer, F; Oechsle, K; Ruf, W; Spath, B; Steinemann, G, 2015) |
| "A small number of patients with germ cell cancer (GCC) receive more than one line of treatment for disseminated disease." | ( Agerbaek, M; Bandak, M; Daugaard, G; Gupta, R; Holm, NV; Kier, MG; Lauritsen, J; Mortensen, MS, 2015) |
| "Male germ cell tumors (GCTs) are curable cancers, yet 10-15 % of patients with metastatic disease fail cisplatin-based first-line treatments." | ( Beyer, J; Bode, PK; Fankhauser, CD; Honecker, F, 2015) |
| "Testicular germ cell tumors (TGCTs) belong to the most chemosensitive solid tumors; however, a small proportion of patients fail to be cured with cisplatin-based chemotherapy." | ( Babal, P; Chovanec, M; Cierna, Z; Hainova, K; Kajo, K; Macak, D; Machalekova, K; Mardiak, J; Mego, M; Miskovska, V; Ondrus, D; Rejlekova, K; Spanik, S; Svetlovska, D, 2016) |
| "Testicular germ cell tumors (TGCTs) are a model for curable cancer because of exquisite chemosensitivity and incorporation of multimodal therapy." | ( Amatruda, JF; Bagrodia, A; Woldu, SL, 2017) |
| "Patients with germ cell cancer receiving upfront platinum-containing chemotherapy between 2004 and 2014 were pooled from the Spanish Germ Cell Cancer Group (SGCCG) registry and reviewed for the presence of VTE." | ( Aparicio, J; Ayala de la Peña, F; Carmona-Bayonas, A; Castellano, D; Cerezuela, P; Duran, I; Fernandez, A; Fernandez, S; García Del Muro, X; Germà-Lluch, JR; Gonzalez-Billalabeitia, E; Guma, J; Hervas, D; Luengo, MI; Luis Aguilar, J; Manneh, R; Margeli, M; Maroto, P; Mellado, B; Rivera, S; Ros, S; Saenz, A; Sanchez-Muñoz, A; Sastre, J; Sobrevilla, N; Valverde, C, 2017) |
| "Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity." | ( Barretta, F; Basso, ME; Biasoni, D; Bisogno, G; Boldrini, R; Boschetti, L; Cecchetto, G; Conte, M; D'Angelo, P; De Leonardis, F; De Pasquale, MD; Di Pinto, D; Inserra, A; Siracusa, F; Spreafico, F; Terenziani, M, 2017) |
| "Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy." | ( Bokemeyer, C; Oing, C; Seidel, C, 2018) |
| "Metastatic germ cell tumors remain potentially curable when treated with salvage chemotherapy at first relapse." | ( Bowers, M; Cozens, K; Cross, N; Hennig, IM; Huddart, R; McKenzie, HS; Mead, G; Rustin, GJS; Wheater, MJ; White, JD, 2018) |
| "Testicular germ cell tumors (TGCTs) are highly sensitive to cisplatin‑based chemotherapy." | ( Chovanec, M; Kalavska, K; Kozovska, Z; Kucerova, L; Macak, D; Mardiak, J; Mego, M; Palacka, P; Pindak, D; Plank, L; Schmidtova, S; Toro, L, 2018) |
| "Testicular germ cell tumors (TGCTs) are unique amongst solid tumors in terms of the high cure rates using chemotherapy for metastatic disease." | ( Andrews, P; Barrett, MT; Bryce, AH; Lenkiewicz, E; Malasi, S; Pagliaro, L; Slack, J; Stanton, M, 2019) |
| "Epigenetic (combination) treatment for germ cell tumors should be further explored in pre-clinical and clinical research for its potential to further improve germ cell tumor treatment." | ( Bokemeyer, C; Nettersheim, D; Oing, C; Skowron, MA, 2019) |
| "Testicular Germ Cell Tumor (TGCT), undoubtedly the seminoma histological variant more than non-seminoma one, is definitely a highly curable disease, with a distinctive sensitivity to cisplatin-based therapy (and for seminomas to radiotherapy) and an outstanding cure rate of nearly 80% even for patients with advanced disease." | ( Berretta, M; Capasso, M; Cavaliere, C; D'Aniello, C; Della Pepa, C; Facchini, G; Facchini, S; Imbimbo, C; Iovane, G; Mollo, G; Pesce, L; Pisconti, S; Rossetti, S, 2019) |
| "The most challenging aspect of germ cell tumor management for the treating physician is knowing the proper indications for surgery." | ( Anand, VK; Arnaout, MM; Cummock, MD; El Asri, AC; Gerges, MM; Greenfield, JP; Schwartz, TH, 2019) |
| "The modern treatment of disseminated germ cell tumors (GCT) relies largely on cisplatin-based regimens, particularly combination chemotherapy with bleomycin, etoposide, and cisplatin." | ( Kollmannsberger, CK; Lavoie, JM, 2019) |
| "Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life-threatening venous thromboembolism (VTE)." | ( Amir, E; Bedard, PL; Bokemeyer, C; Brito, M; Castellano, D; Cheng, T; Fankhauser, C; Fléchon, A; Garcia Del Muro, X; Gonzalez-Billalabeitia, E; Hamid, AA; Heng, DYC; Hermanns, T; Kitson, R; Kwan, EM; Ottaviano, M; Palmieri, G; Patrikidou, A; Reid, A; Ruiz-Morales, JM; Rumyantsev, A; Seidel, C; Tran, B; Tryakin, A, 2020) |
| "Patients with relapsed germ cell tumors (GCTs) can be cured with salvage chemotherapy." | ( Abonour, R; Adra, N; Albany, C; Althouse, SK; Einhorn, LH; Hanna, NH; Zaid, MA; Zhang, KJ, 2020) |
| "Metastatic germ cell cancer of the testis is characterized by favorable prognosis since effective treatment methods are available even in cases of extensive disease." | ( Aziri, R; Chovanec, M; Hulova, S; Kolnikova, G; Mardiak, J; Mego, M; Palacka, P; Pindak, D; Rejlekova, K; Vulev, I, 2020) |
| "Testicular germ cell cancer (TC) incidence peaks during reproductive age, but knowledge on fertility after treatment is insufficient." | ( Bandak, M; Daugaard, G; Dehlendorff, C; Jensen, A; Kreiberg, M; Lauritsen, J; Rosenvilde, J; Wagner, T, 2022) |
| "Testicular germ cell tumors (TGCTs) are aggressive but sensitive to cisplatin-based chemotherapy." | ( Baldwin, H; Bikorimana, E; Boyd, RI; Corbet, AK; Fazal, Z; Freemantle, SJ; Hattab, A; Shahid, K; Shokry, D; Singh, R; Spinella, MJ; Tomlin, M; Yerby, C, 2022) |
| "Central review by an expert germ cell tumor pathologist provides important additional information to guide therapy." | ( Billmire, DF; Dicken, BJ; Fallahazad, N; Frazier, AL; Hazard, FK; Krailo, M; Nuño, M; Pashankar, F; Rich, B; Shaikh, F, 2022) |
| "Treatment of (cisplatin-resistant) germ cell tumors (GCT), urothelial, renal, and prostate carcinoma cells with the HDAC, BET, and dual inhibitors decreased cell viability, induced apoptosis, and affected the cell cycle." | ( Albers, P; Alves Avelar, LA; Bremmer, F; Burmeister, A; Fischer, F; Hoffmann, MJ; Höfmann, S; Köhrer, K; Kurz, T; Müller, MR; Nettersheim, D; Niegisch, G; Petzsch, P; Seiwert, A; Skowron, MA; Stephan, A; Torres-Gomez, H, 2022) |
| "Malignant extracranial germ cell tumors (GCTs) are rare in pediatric patients and are usually extremely sensitive to chemotherapy." | ( Faria, TMV; Guimarães, RFDC; Jorge, GEM; Lopes, LF; Macedo, CRPD; Navarro, G; Seber, A; Vidal, DO; Villela, NC; Zecchin, VG, 2023) |
| "Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20-30% of patients relapse." | ( Al-Ezzi, EM; Crump, M; Hamilton, RJ; Hansen, AR; Hotte, SJ; Jiang, DM; Kollmannsberger, CK; Kuruvilla, J; Nappi, L; North, SA; Soulières, D; Winquist, E; Wood, L; Zahralliyali, A, 2023) |
| "Vaginal malignant germ cell tumors (MGCT) are rare, occurring in children less than 2 years old and raise the question of the optimal local treatment." | ( Chargari, C; Coppin, R; Faure-Conter, C; Fresneau, B; Guérin, F; Martelli, H; Orbach, D; Pasquet, M; Patte, C; Piguet, C; Saumet, L; Sudour-Bonnange, H; Vérité, C, 2023) |